Eggermont, Alexander M M <br/><br/>
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.  [electronic resource] 

 -  The New England journal of medicine  May 2018 
 - 1789-1801 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa1802357  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--adverse effects<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>B7-H1 Antigen--analysis<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Intention to Treat Analysis<br/>Kaplan-Meier Estimate<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Neoplasm Staging<br/>Quality of Life<br/>Skin Neoplasms--drug therapy<br/>Survival Rate